The Belgian biotechnology company Promethera has been successfully administering a mesenchymal stem cell [MSC] therapy to treat severe liver disease - Acute-on-Chronic Liver Failure [ACLF], which was previously only treated with organ transplants. The treatment called HepaStem utilizes mesenchymal stem cells cultured from livers which, when delivered to the patient intravenously, release support and anti-inflammatory factors for existing liver cells. The company, after conducting Phase I studies to determine the safety of the treatment, is conducting Phase II clinical trials to identify optimal dosage parameters and measure treatment efficacy.
As available organs for transplants are scarce, having a non-organ transplant option would help patients suffering from ACLF restore their own livers.
Advances in stem cell based regenerative treatments are creating more effective treatment options for patients suffering from a wide variety of disease, trauma and injury. To learn more about stem cells, and how families can protect their future health with stem cells, visit StemSave or call 877-783-6728 (877-StemSave) today.
The Future of Regenerative Medicine is Now™
To view the full article, click here.